A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients

A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients

Abstract Background Only a few prospective trials exist regarding the use of novel direct-acting antiviral agents (DAAs) in kidney transplant recipients (KTR) with chronic hepatitis C virus (HCV) infection. Methods This prospective single-center trial evaluated treatment with daclatasvir (DCV) and s...

Full description

Bibliographic Details
Main Authors: Michael Duerr, Eva V. Schrezenmeier, Lukas J. Lehner, Léon Bergfeld, Petra Glander, Stephan R. Marticorena Garcia, Christian E. Althoff, Ingolf Sack, Susanne Brakemeier, Kai-Uwe Eckardt, Klemens Budde, Fabian Halleck
Format: Article
Language:English
Published: BMC 2019-02-01
Series:BMC Nephrology
Subjects:
Kidney transplantation
HCV infection
Direct-acting antivirals
Daclatasvir
Sofosbuvir
Online Access:http://link.springer.com/article/10.1186/s12882-019-1218-0

Internet

http://link.springer.com/article/10.1186/s12882-019-1218-0

Similar Items